Drug intelligence / Profile preview

PIXY321 + erythropoietin

Development stage: Discontinued
Lead developer: Amgen
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

PIXY321 + erythropoietin is a combination of two hematopoietic growth factors. PIXY321 is a genetically engineered fusion protein of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3) designed to stimulate multilineage hematopoiesis. Erythropoietin is a glycoprotein hormone that stimulates red blood cell production. The combination was investigated for its potential to ameliorate chemotherapy-induced myelosuppression and enhance hematopoietic recovery following high-dose chemotherapy and bone marrow transplantation.

Other names: GM-CSF/IL-3 fusion protein + erythropoietin

Targets

IL3RA (Interleukin 3 Receptor)Erythropoietin ReceptorCSF2R (Granulocyte-macrophage colony-stimulating factor receptor)

Beyond the preview

Go deeper on PIXY321 + erythropoietin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PIXY321 + erythropoietin.

Explore the full profile